$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000165495422012862 Filed on September 22, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$869.7K	$770.7K	$1.468M
YoY Change	445.3%	339.95%	-878.61%
Cost Of Revenue	$86.50K	$87.52K	$217.5K
YoY Change	60.39%	131.53%	47.14%
Gross Profit	$783.2K	$683.2K	$1.251M
YoY Change	641.97%	397.29%	-471.81%
Gross Profit Margin	90.05%	88.64%	85.19%
Selling, General & Admin	$3.509M	$6.348M	$16.51M
YoY Change	-8.54%	6.68%	-4.76%
% of Gross Profit	448.04%	929.15%	1319.98%
Research & Development	$6.027M	$7.436M	$21.33M
YoY Change	72.95%	113.57%	64.99%
% of Gross Profit	769.59%	1088.4%	1704.93%
Depreciation & Amortization	$59.63K	$42.43K	$126.7K
YoY Change	374.76%	237.82%	147.79%
% of Gross Profit	7.61%	6.21%	10.13%
Operating Expenses	$9.622M	$13.78M	$38.06M
YoY Change	30.47%	46.14%	25.75%
Operating Profit	-$8.753M	-$13.10M	-$36.59M
YoY Change	21.3%	40.95%	19.57%
Interest Expense	$9.602K	$333.5K	$29.68K
YoY Change	70.52%	-244.02%	-113.98%
% of Operating Profit
Other Income/Expense, Net	$497.3K		$390.1K
YoY Change	382.13%		-283.69%
Pretax Income	-$8.255M	-$12.77M	-$36.20M
YoY Change	16.07%	-8.37%	7.74%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.255M	-$12.77M	-$36.20M
YoY Change	16.07%	-8.37%	7.74%
Net Earnings / Revenue	-949.28%	-1656.54%	-2465.06%
Basic Earnings Per Share
Diluted Earnings Per Share	-$856.8K	-$1.335M	-$3.793M
COMMON SHARES
Basic Shares Outstanding	9.290M shares	231.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.19M	$29.94M	$29.94M
YoY Change	-60.33%	-50.19%	-50.19%
Cash & Equivalents	$21.19M	$29.94M	$29.94M
Short-Term Investments
Other Short-Term Assets	$2.105M	$1.932M	$1.932M
YoY Change	-28.57%	-36.84%	-36.84%
Inventory	$858.0K	$944.5K	$944.5K
Prepaid Expenses
Receivables	$2.023M	$1.780M	$1.780M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$26.18M	$34.60M	$34.60M
YoY Change	-55.17%	-47.51%	-47.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$620.9K	$539.3K	$1.418M
YoY Change	343.44%	468.79%	6.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$1.465M	$1.475M	$1.475M
YoY Change	9.03%	6.13%	6.13%
TOTAL ASSETS
Total Short-Term Assets	$26.18M	$34.60M	$34.60M
Total Long-Term Assets	$1.465M	$1.475M	$1.475M
Total Assets	$27.64M	$36.07M	$36.07M
YoY Change	-53.72%	-46.4%	-46.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.774M	$3.158M	$3.158M
YoY Change	394.8%	392.88%	392.88%
Accrued Expenses	$6.117M	$6.875M	$7.246M
YoY Change	22.55%	18.59%	17.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$102.3K	$100.9K	$100.9K
YoY Change
Total Short-Term Liabilities	$15.86M	$16.26M	$16.26M
YoY Change	62.05%	54.68%	54.68%
LONG-TERM LIABILITIES
Long-Term Debt	$126.3K	$152.4K	$152.4K
YoY Change
Other Long-Term Liabilities	$2.740M	$2.861M	$3.391M
YoY Change	-55.57%	-54.09%	-52.47%
Total Long-Term Liabilities	$2.740M	$2.861M	$3.543M
YoY Change	-55.57%	-54.09%	-50.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.86M	$16.26M	$16.26M
Total Long-Term Liabilities	$2.740M	$2.861M	$3.543M
Total Liabilities	$19.19M	$19.80M	$19.80M
YoY Change	14.49%	12.23%	12.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.2M	-$388.0M
YoY Change	10.4%	10.29%
Common Stock	$92.91K	$92.71K
YoY Change	-95.98%	-95.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.449M	$16.27M	$16.27M
YoY Change
Total Liabilities & Shareholders Equity	$27.64M	$36.07M	$36.07M
YoY Change	-53.72%	-46.4%	-46.4%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$8.255M	-$12.77M	-$36.20M
YoY Change	16.07%	-8.37%	7.74%
Depreciation, Depletion And Amortization	$59.63K	$42.43K	$126.7K
YoY Change	374.76%	237.82%	147.79%
Cash From Operating Activities	-$24.73K	-$7.719M	$18.36K
YoY Change	-99.61%	-9.58%	-100.08%
INVESTING ACTIVITIES
Capital Expenditures	-$141.2K	-$37.11K	$261.4K
YoY Change	144.51%		-4669.48%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$141.2K	-$37.11K	-$261.4K
YoY Change	144.49%		4469.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$8.581M	-24.41K	-$29.92M
YoY Change	4140.77%		31855.09%
NET CHANGE
Cash From Operating Activities	-$24.73K	-7.719M	$18.36K
Cash From Investing Activities	-$141.2K	-37.11K	-$261.4K
Cash From Financing Activities	-$8.581M	-24.41K	-$29.92M
Net Change In Cash	-$8.747M	-7.780M	-$30.17M
YoY Change	30.87%	-8.86%	32.61%
FREE CASH FLOW
Cash From Operating Activities	-$24.73K	-$7.719M	$18.36K
Capital Expenditures	-$141.2K	-$37.11K	$261.4K
Free Cash Flow	$116.5K	-$7.682M	-$243.0K
YoY Change	-101.83%	-10.01%	-98.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4030	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4030	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9201988	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9270947	shares
CY2022Q2	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1623795	usd
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-15543
CY2022	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
CY2022	dei	City Area Code CityAreaCode	609
CY2022	dei	Local Phone Number LocalPhoneNumber	495‑2200
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2022	dei	Trading Symbol TradingSymbol	PTN
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	115996632	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9290481	shares
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29939154	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780020	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1580443	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	944471	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	1162000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1932454	usd
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3059679	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	34596099	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	65907041	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539314	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94817	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	878465	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1237813	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2022Q2	us-gaap	Assets Assets	36070794	usd
CY2021Q2	us-gaap	Assets Assets	67296587	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3157617	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	640650	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6875216	usd
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5797378	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	371124	usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	351853	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	100921	usd
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5754986	usd
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16259864	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10511788	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	529398	usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	900520	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	152407	usd
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2861250	usd
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6232907	usd
CY2022Q2	us-gaap	Liabilities Liabilities	19802919	usd
CY2021Q2	us-gaap	Liabilities Liabilities	17645215	usd
CY2022Q2	ptn	Escrowed Proceeds EscrowedProceeds	-15000000	usd
CY2021Q2	ptn	Escrowed Proceeds EscrowedProceeds	0	usd
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4030	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	92709	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	92020	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	404168822	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	401354709	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387993696	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-351795397	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36070794	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67296587	usd
CY2022	ptn	License And Contract LicenseAndContract	250000	usd
CY2021	ptn	License And Contract LicenseAndContract	94689	usd
CY2022	us-gaap	Revenues Revenues	1468457	usd
CY2021	us-gaap	Revenues Revenues	-188597	usd
CY2022	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-2784192	usd
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	80172849	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3168656	usd
CY2021	ptn	Taxes Withheld Related To Restricted Stock Units Amount TaxesWithheldRelatedToRestrictedStockUnitsAmount	-93638	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-33596495	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2505538	usd
CY2022	ptn	Issuance Of Redeemable Convertible Preferred Stock And Warrants Amount IssuanceOfRedeemableConvertiblePreferredStockAndWarrantsAmount	234443	usd
CY2022	ptn	Taxes Withheld Related To Restricted Stock Units Amount TaxesWithheldRelatedToRestrictedStockUnitsAmount	-221311	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	280000	usd
CY2022	ptn	Option Exercises Amount OptionExercisesAmount	16132	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36198299	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2022	ptn	Gain On Termination Agreement GainOnTerminationAgreement	0	usd
CY2021	ptn	Gain On Termination Agreement GainOnTerminationAgreement	19084192	usd
CY2022	ptn	Non Cash Warrant Expense NonCashWarrantExpense	234443	usd
CY2021	ptn	Non Cash Warrant Expense NonCashWarrantExpense	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1004400	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7560000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261374	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5722	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	280000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16132	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	usd
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82852270	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29939154	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	usd
CY2022	ptn	Accrued Expenses AccruedExpenses	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>Accrued Expenses –</em> Third parties perform a significant portion of the Company’s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2851959	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1650589	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	363780	shares
CY2021	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	326563	shares
CY2021Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	454750	usd
CY2021Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	259468	usd
CY2022	ptn	License And Contract Revenue LicenseAndContractRevenue	250000	usd
CY2017Q4	ptn	License Agreement LicenseAgreement	94689	usd
CY2021Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	569370	usd
CY2021Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	1200000	usd
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1145461	usd
CY2021Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3059679	usd
CY2021Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	59730428	usd
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	418471	usd
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	636000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	944471	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	1162000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	294293	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	287440	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	114418	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	108023	usd
CY2022	ptn	Total Lease Cost TotalLeaseCost	408711	usd
CY2021	ptn	Total Lease Cost TotalLeaseCost	395463	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	111899	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	111899	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	46625	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17095	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	253328	usd
CY2021Q2	ptn	Clinical Study Costs ClinicalStudyCosts	778705	usd
CY2021Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	6232907	usd
CY2022Q2	us-gaap	Contributions In Aid Of Construction ContributionsInAidOfConstruction	220864	usd
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	84094	usd
CY2021Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	1839724	usd
CY2022Q2	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	0	usd
CY2021Q2	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	2340000	usd
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	185485	usd
CY2021Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	5797378	usd
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	usd
CY2021Q2	us-gaap	Contributions In Aid Of Construction ContributionsInAidOfConstruction	168210	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	20.00
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	796097	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y4M24D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	141844	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	22732	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	18.75
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39910	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	23.75
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	875299	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.00
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1744	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2017Q4	ptn	Performance Based Restricted Stock PerformanceBasedRestrictedStock	43000	shares
CY2020Q4	ptn	Performance Based Restricted Stock PerformanceBasedRestrictedStock	4700	shares
CY2022Q2	us-gaap	Fair Value Hedges At Fair Value Net FairValueHedgesAtFairValueNet	602760	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.691	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.683	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022	ptn	Weighted Average Grant Date Fair Value WeightedAverageGrantDateFairValue	2.68
CY2021	ptn	Weighted Average Grant Date Fair Value WeightedAverageGrantDateFairValue	8.50
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2070413	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	593629	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	518620	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	131352	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	129774	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	6426	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	16442	shares
CY2022	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-69406	shares
CY2021	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-38323	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	649149	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	593629	shares
CY2022	ptn	Vested Shares Not Issued VestedSharesNotIssued	363780	usd
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	50.00
CY2022Q2	ptn	Fair Value Of Awards FairValueOfAwards	913750	shares
CY2021Q2	ptn	Fair Value Of Awards FairValueOfAwards	569500	shares
CY2022Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.50	pure
CY2022	ptn	Vesting Of Restricted Share VestingOfRestrictedShare	16191	shares
CY2021	ptn	Vesting Of Restricted Share VestingOfRestrictedShare	6671	shares
CY2022	ptn	Aggregate Value AggregateValue	221311	usd
CY2021	ptn	Aggregate Value AggregateValue	93638	usd
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001654954-22-012862-index-headers.html	Edgar Link	pending
0001654954-22-012862-index.html	Edgar Link	pending
0001654954-22-012862.txt	Edgar Link	pending
0001654954-22-012862-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20220630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ptn_10k.htm	Edgar Link	pending
ptn_10kimg2.jpg	Edgar Link	pending
ptn_10kimg3.jpg	Edgar Link	pending
ptn_ex23.htm	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
ptn-20220630_pre.xml	Edgar Link	unprocessable
ptn_10k_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ptn-20220630_cal.xml	Edgar Link	unprocessable
ptn-20220630_def.xml	Edgar Link	unprocessable
ptn-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q3 Form 10-K Financial Statement

#000165495422012862 Filed on September 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q3 Form 10-K Financial Statement

#000165495422012862 Filed on September 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn